ArticleHaematologica2009

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.

Claire M Lucas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.